Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID07190755

Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Curative Treatment of Head and Neck Squamous Cell Carcinoma With Radiotherapy or Chemoradiotherapy

Led by Centre Henri Becquerel · Updated on 2025-12-30

192

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

Sponsors

C

Centre Henri Becquerel

Lead Sponsor

R

Resilience

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the impact of remote symptom monitoring on patients with Head and Neck Squamous Cell Carcinoma (HNSCC) who are receiving curative radiotherapy or chemoradiotherapy. The study aims to see if digital tools can help detect problems early and reduce the proportion of patients experiencing at least 5% weight loss within three months after treatment. This approach may help improve care by addressing symptoms before they worsen. Participants will be randomly assigned to one of two groups. One group receives standard care without additional monitoring. The other group uses Resilience PRO, a mobile phone app that regularly asks about symptoms and sends alerts to the care team when important issues arise. This allows timely adjustments to treatment and support. The study will continue to monitor survival at 12 and 18 months after treatment. Throughout the study, participants will be followed for symptom reporting, weight changes, and survival outcomes. The research team will collect data via the app and standard clinical visits. The main measure is the impact of remote monitoring on weight loss three months after treatment. Secondary measures include survival rates up to 18 months. The total participation period extends at least 18 months with ongoing evaluation of health status and treatment effects.

CONDITIONS

Brief Title

Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient aged over 18 and under 75 years with WHO score less than 2
  • Treated for localized head and neck squamous cell carcinoma with curative radiotherapy or chemoradiotherapy
  • Signed the informed consent form
  • Affiliated with or beneficiary of a social protection scheme
  • Access to a smartphone or the internet
Not Eligible

You will not qualify if you...

  • History of other cancer less than 2 years ago or progressive disease
  • History of ear, nose, and throat radiotherapy
  • Pregnant or breastfeeding women
  • Adults under guardianship, curatorship, or judicial protection
  • Participation in another therapeutic study
  • Inability to understand the study or comply with its requirements (language, psychological, geographical issues)
  • Blindness preventing use of the telemonitoring app

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Duration of radiotherapy or chemoradiotherapy treatment

Participants receive curative radiotherapy or chemoradiotherapy for localized head and neck squamous cell carcinoma. Those in the intervention group use a mobile app to report symptoms remotely for timely care adjustments.

Regular visits as part of standard care; symptom reporting via mobile app as applicable

Follow-up

Duration - Up to 18 months after treatment

Participants are monitored for impact of symptom monitoring on weight loss and survival after treatment completion.

Follow-up visits as per standard care schedule

Trial Site Locations

Total: 2 locations

1

Centre Henri Becquerel

Rouen, France

Actively Recruiting

2

Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France

Not Yet Recruiting

Loading map...

Research Team

S

Sebastien Thureau, MD,PhD

D

Doriane Richard, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Similar Trials

[68Ga]Ga-FAPI-46 PET/CT in Early Detection of Lymph Node Met...

Head and Neck Squamous Cell Carcinoma HNSCC

Actively Recruiting

1 location

A First-in-Human, Open-Label Phase 1 Study of EPI-326 in Pat...

Epidermal Growth Factor

Actively Recruiting

6 locations

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinet...

Head and Neck Squamous Cell Carcinoma HNSCC

Actively Recruiting

6 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here